Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 은창수 | - |
dc.date.accessioned | 2016-08-19T02:32:14Z | - |
dc.date.available | 2016-08-19T02:32:14Z | - |
dc.date.issued | 2015-03 | - |
dc.identifier.citation | SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, v. 50, NO 3, Page. 312-320 | en_US |
dc.identifier.issn | 0036-5521 | - |
dc.identifier.issn | 1502-7708 | - |
dc.identifier.uri | http://www.tandfonline.com/doi/abs/10.3109/00365521.2014.1000960#.V6fgWbckrcs | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/22614 | - |
dc.description.abstract | Objective. Real-world epidemiological data on tuberculosis (TB) infection in patients with inflammatory bowel disease (IBD) receiving TNF-alpha inhibitors are scarce. We investigated the risks for and case characteristics of TB in a large cohort of IBD patients treated with TNF-alpha inhibitors in Korea, where TB is endemic. Materials and methods. We performed an observational study on all TB cases identified in a cohort of 873 IBD subjects treated with TNF-alpha inhibitors from January 2001 to December 2013. The standardized incidence ratio (SIR) of TB was calculated using data from the matched general population. Results. A total of 25 newly developed TB cases were identified in the cohort (pulmonary TB, 84% [21/25]; extrapulmonary TB, 16% [4/25]). The adjusted SIR of TB was 41.7 (95% confidence interval, 25.3-58.0), compared with that of the matched general population. Nineteen of the 25 patients (76%) developed TB within 2-62 months of initiation of TNF-alpha inhibitor treatment despite screening negative for latent TB infection (LTBI), whereas three patients with LTBI (12%, 3/25) developed TB 3 months after completion of chemoprophylaxis. The outcomes of TB treatment were mostly favorable, although one death from peritoneal TB was noted. The type of TNF-alpha inhibitor prescribed (infliximab) was a significant predictor of TB (p = 0.033). Conclusions. TNF-alpha inhibitor treatment strikingly increases the risk of TB infection in an IBD population from a TB endemic area. Continuous evaluation of the development of de novo TB infection in IBD patients subjected to long-term TNF inhibitor therapy is mandatory. | en_US |
dc.description.sponsorship | Kyung Hee University | en_US |
dc.language.iso | en | en_US |
dc.publisher | INFORMA HEALTHCARE | en_US |
dc.subject | inflammatory bowel disease | en_US |
dc.subject | latent tuberculosis infection | en_US |
dc.subject | tuberculosis | en_US |
dc.subject | tumor necrosis factor-alpha inhibitor | en_US |
dc.title | Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-alpha inhibitor | en_US |
dc.type | Article | en_US |
dc.relation.no | 3 | - |
dc.relation.volume | 50 | - |
dc.identifier.doi | 10.3109/00365521.2014.1000960 | - |
dc.relation.page | 312-320 | - |
dc.relation.journal | SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY | - |
dc.contributor.googleauthor | Byun, Ja Min | - |
dc.contributor.googleauthor | Lee, Chang Kyun | - |
dc.contributor.googleauthor | Rhee, Sang Youl | - |
dc.contributor.googleauthor | Kim, Hyo-Jong | - |
dc.contributor.googleauthor | Im, Jong Pil | - |
dc.contributor.googleauthor | Park, Dong Il | - |
dc.contributor.googleauthor | Eun, Chang Soo | - |
dc.contributor.googleauthor | Jung, Sung-Ae | - |
dc.contributor.googleauthor | Shin, Jeong Eun | - |
dc.contributor.googleauthor | Lee, Kang-Moon | - |
dc.contributor.googleauthor | Lee, Sang Joon | - |
dc.relation.code | 2015002312 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | cseun | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.